CD28 and Miyoshi myopathy: While only a few samples scored positive in the NDMM samples (19%), the majority of MM cells from RRMM patients aberrantly expressed CD28 (86%), making the dual CD/38/CD28 targeting of SAR442257 attractive for this challenging patient population.